Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Calibr-Skaggs Expands License Agreement with AbbVie for Cell Therapies in Solid Tumors
Details : Under the agreement, AbbVie will explore Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapies in solid tumor indications and autoimmune diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 02, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the collaboration, AbbVie will develop and commercialize switchable CAR T-cell therapies arising from the independent preclinical research conducted by Calibr, with the goal of advancing its pipeline of therapeutic programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 26, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : CLB073
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Gates MRI
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment.
Product Name : CLB073
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 15, 2023
Lead Product(s) : CLB073
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Gates MRI
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : eOD-GT8 60mer,AS01B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : IAVI
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EOD-GT8 60mer showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
Product Name : eOD-GT8 60mer
Product Type : Vaccine
Upfront Cash : Inapplicable
March 02, 2021
Lead Product(s) : eOD-GT8 60mer,AS01B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : IAVI
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : C5-RIBOTAC
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Scientists Discover Small Molecule that Targets, Destroys RNA Sequence of Virus that Causes COVID-19
Details : Scientists from Scripps Research have created drug-like compounds that, in human cell studies, bind and destroy the coronavirus’ clutch-like device which helps in viral replication, thus ceasing its spread.
Product Name : C5-RIBOTAC
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2020
Lead Product(s) : C5-RIBOTAC
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clues to COVID-19 coronavirus’s vulnerability emerge from an antibody against SARS
Details : The study, published in Science, is the first to map a human antibody’s interaction with the new coronavirus at near-atomic-scale resolution.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 04, 2020
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable